CompletedNot Applicable

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

United States327 participantsStarted 2024-02-19

Plain-language summary

This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab + Lenvatinib combination therapy

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age 18 years and older with diagnosis of Advanced Renal Cell Carcinoma (aRCC) with predominantly clear-cell histology
. Received any of the following therapies in the first-line setting:
. Nivolumab + Ipilimumab between 8/1/2021 and 6 months prior to data collection
. Pembrolizumab + Lenvatinib between 8/1/2021and 6 months prior to data collection
. Participant had at least 6 months of follow-up from initiation of index treatment (patients who deceased prior to 6 months since index treatment initiation would still be eligible)

Exclusion criteria

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Participant year of birth

Timeframe: Baseline

Participant sex at birth

Timeframe: Baseline

Participant primary payer

Timeframe: Baseline

Participant race

Timeframe: Baseline

Participant ethnicity

Timeframe: Baseline

Participant U.S. state of residence

Timeframe: Baseline

Participant initial Renal Cell Carcinoma (RCC) diagnoses

Timeframe: Baseline

American Joint Committee on Cancer (AJCC) TNM stage

Timeframe: Baseline

Trial details

NCT IDNCT06345183

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-04-04

View on ClinicalTrials.gov More Advanced Renal Cell Carcinoma (aRCC) trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age 18 years and older with diagnosis of Advanced Renal Cell Carcinoma (aRCC) with predominantly clear-cell histology
. Received any of the following therapies in the first-line setting:
. Nivolumab + Ipilimumab between 8/1/2021 and 6 months prior to data collection
. Pembrolizumab + Lenvatinib between 8/1/2021and 6 months prior to data collection
. Participant had at least 6 months of follow-up from initiation of index treatment (patients who deceased prior to 6 months since index treatment initiation would still be eligible)

Exclusion criteria

What they're measuring

Participant year of birth

Timeframe: Baseline

Participant sex at birth

Timeframe: Baseline

Participant primary payer

Timeframe: Baseline

Participant race

Timeframe: Baseline

Participant ethnicity

Timeframe: Baseline

Participant U.S. state of residence

Timeframe: Baseline

Participant initial Renal Cell Carcinoma (RCC) diagnoses

Timeframe: Baseline

American Joint Committee on Cancer (AJCC) TNM stage

Timeframe: Baseline